REG - Physiomics PLC - Completion of Placing and WRAP Retail Offer Launch

PhysiomicsAnnouncement

Today 07:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20260317:nRSQ9388Wa&default-theme=true

RNS Number : 9388W  Physiomics PLC  17 March 2026

17 March 2026

 

 

Physiomics plc

("Physiomics" or the "Company")

 

Physiomics completes Placing to fund growth opportunities

Launch of WRAP Retail Offer

 

 

Physiomics plc (AIM: PYC), a leading mathematical modelling, data science and
biostatistics company supporting the development of new therapeutics and
personalised medicine solutions, is pleased to announce that it has completed
a revised placing, conditional on admission to trading on AIM, of, in
aggregate, £490,000.00 (gross) from the issue of 122,500,000 new ordinary
shares (the "Placing Shares") at an issue price of £0.004 per Placing Share
(the "Placing Price") through the Company's broker, Hybridan LLP (the
"Placing"). The Placing Price represents a discount of approximately 14 per
cent. to the mid-market closing price of an existing ordinary share on 16
March 2026 (being the latest practicable date prior to this announcement).

 

The Company will also shortly be launching a revised retail offering to the
Company's existing shareholders to raise up to an additional £110,000.00 by
way of the issue of a further 27,500,000 new ordinary shares (the "WRAP Retail
Offer Shares") at the Placing Price.

 

The placing and retail offer previously announced by the Company on 10 March
2026 have been cancelled in substitution for the placing announced by way of
this announcement. The cancellation of the previous placing followed a review
by the Board of the terms and structure of that placing and the later receipt
by the Company on 13 March 2026 of a shareholder requisition under section 303
of the Companies Act 2006, details of which are set out in the Company's
announcement yesterday. The Board considered it appropriate in these
circumstances to relaunch the placing on revised terms, at a price of £0.004
per share, which represents an improvement on the price of the cancelled
placing and reflects the level of investor demand received. It is noted that,
as the Company's existing share issuance authorities are sufficient to cover
the issue of the Placing Shares and the maximum number of WRAP Retail Offer
Shares, it is intended that the General Meeting called for 7 April 2026, as
announced on 10 March 2026, will be cancelled. The Board believes the Placing
is in the best interests of the Company and its shareholders as a whole.

 

In order to further develop its business and continue its growth trajectory,
the Company is raising funds to carry out the following activities and for
general working capital:

·    Consulting Services (Modelling & Simulation and Biometrics)

o  Investment in business development and marketing to expand offering across
both service lines, including further development of later clinical phases and
engagement of large biopharmaceutical companies and contract research
organisations; and

o  Expansion of internal capabilities to support both services, including
development of new processes and data management solutions to support the
expanding offerings.

·    Personalised Medicine Tool Development

o  Continue development of the Company's Personalised Dosing Software.

·    Corporate

o  Exploration of strategic options to accelerate growth of modelling and
biometrics services and creation of new service-lines.

 

The Company has made significant progress since its last placing in February
2025, including:

·    Reporting a 46% year-on-year growth of total income for the financial
year ending 30 June 2025 and reporting a record half-year for total income for
the six-month period ending 31 December 2025. To date in FY26, the Company has
twice exceeded its best monthly revenue in comparison to FY 2025 with one
month achieving over £110k.

·    Appointment of Mr Jesse Thissen as Head of Biometrics and the
Company's first four contract awards for this new service line.

·    Continued expansion of the modelling and simulation service line into
new therapeutic areas, with projects supporting the development of new drugs
targeting arthritis, chronic obstructive pulmonary disease, coeliac disease,
and infectious diseases.

·    Continued diversification of client base, whilst still winning new
business with long-standing relationships such as Numab Therapeutics.

·    Implementation of the Company's Personalised Dosing Software onto the
DoseMeRx platform and expanded relationship with DoseMe Inc.

·    One peer-reviewed scientific article was published in partnership
with Ankyra Therapeutics, accompanied by several thought leadership pieces and
blog posts.

 

Retail Offering:

 

The Company is pleased to announce that a retail offer to existing
shareholders will be shortly launched via the Winterflood Retail Access
Platform ("WRAP"), to raise up to an additional £110,000.00 (the "WRAP Retail
Offer"), through the issue of up to 27,500,000 new ordinary shares (the "WRAP
Retail Offer Shares"), at the Placing Price.

 

The proceeds of the WRAP Retail Offer will be utilised in the same way as the
proceeds of the Placing. For the avoidance of doubt, the WRAP Retail Offer is
not part of the Placing. Completion of the WRAP Retail Offer is conditional,
inter alia, upon the completion of the Placing, but completion of the Placing
is not conditional on the completion of the WRAP Retail Offer. The WRAP Retail
Offer is conditional on the WRAP Retail Offer Shares being admitted to
trading.

 

The Company values its shareholder base and believes that it is appropriate to
provide its existing retail shareholders in the United Kingdom the opportunity
to participate in its fundraising.

 

The WRAP Retail Offer is expected to close at midday on 18 March 2026.

 

Admission and Total Voting Rights

 

Application will be made for the Placing Shares to be issued pursuant to the
Placing and the WRAP Retail Offer Shares to be issued pursuant to the WRAP
Retail Offer and each to be admitted to trading on AIM and dealing is expected
to commence on or around 20 March 2026 ("Admission"). A further announcement
regarding the enlarged issued share capital for the purposes of the Financial
Conduct Authority's Disclosure Guidance and Transparency Rules will be made
following completion of the Placing and the WRAP Retail Offer.

 

 

Dr Peter Sargent, CEO, commented:

 

"The Board is delighted by the continued support from our long-term
shareholders who have decided to back the Company at a higher price than our
previously announced fundraise on 10(th) March. This is validation that our
growth plans are supported, and Directors believe that this growth will
continue and that the Company is on track to meet market expectations for this
current year, which would represent a record year for total income of 27%
growth based on market expectations."

 

 

 

Enquiries:

 

Physiomics plc

Dr Peter Sargent, CEO

+44 (0)1235 841575

 

Hybridan LLP (Broker)

Claire Louise Noyce

+44 (0) 203 764 2341

 

Strand Hanson Limited (NOMAD)

James Dance & James Bellman

+44 (0)20 7409 3494

 

The information communicated within this announcement is deemed to constitute
inside information as stipulated under the Market Abuse Regulation (EU) No
596/2014 which is part of UK law by virtue of the European Union (Withdrawal)
Act 2018 as amended by virtue of the Market Abuse (Amendment) (EU Exit)
Regulations 2019. Upon publication of this announcement, this inside
information is now considered to be in the public domain.

 

The Directors of the Company accept responsibility for the content of this
announcement.

 

Notes to Editor

 

About Physiomics

 

Physiomics plc combines expertise across Modelling & Simulation,
Biostatistics, Data Science and Bioinformatics, together with deep
biology expertise, to help biotech and pharma companies streamline their drug
development journeys. Our approach is to help derive insight from all
relevant and often disparate data in order to de-risk decision making and
optimise research design across discovery, pre-clinical and clinical
studies. Through use of cutting-edge computational
tools, bespoke models and our proprietary Virtual Tumour technology,
the Physiomics team has informed the development of over 140 commercial
projects, with over 125 targets and drugs modelled. Clients include
Merck KGaA, Astellas, Bicycle Therapeutics, Numab Therapeutics &
CRUK.  

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  MSCFIFVRVEIDLIR



            Copyright 2019 Regulatory News Service, all rights reserved